Literature DB >> 19189991

The effects of the coverage gap on drug spending: a closer look at Medicare Part D.

Yuting Zhang1, Julie Marie Donohue, Joseph P Newhouse, Judith R Lave.   

Abstract

We calculated prescription drug usage in two groups of Medicare beneficiaries: employer group with no coverage gap, and individual Part D group with no coverage or some generic drug coverage in the coverage gap. Among those with employer coverage, 40 percent reached the doughnut hole, compared with 25 percent of those without such coverage. Overall, 5 percent went through the doughnut hole to reach the catastrophic coverage level. Those lacking coverage in the doughnut hole reduced their drug use by 14 percent; those with generic coverage reduced their use by 3 percent. Coverage of generic drugs with a $0-$10 copayment in the doughnut hole could be financed by, at most, a six-to-nine-percentage-point increase in initial coinsurance.

Entities:  

Mesh:

Year:  2009        PMID: 19189991      PMCID: PMC2859617          DOI: 10.1377/hlthaff.28.2.w317

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  5 in total

1.  Adverse selection and the challenges to stand-alone prescription drug insurance.

Authors:  Mark V Pauly; Yuhui Zeng
Journal:  Front Health Policy Res       Date:  2004

2.  Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs.

Authors:  John Hsu; Vicki Fung; Mary Price; Jie Huang; Richard Brand; Rita Hui; Bruce Fireman; Joseph P Newhouse
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

3.  The effect of incentive-based formularies on prescription-drug utilization and spending.

Authors:  Haiden A Huskamp; Patricia A Deverka; Arnold M Epstein; Robert S Epstein; Kimberly A McGuigan; Richard G Frank
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

4.  Pharmacy benefits and the use of drugs by the chronically ill.

Authors:  Dana P Goldman; Geoffrey F Joyce; Jose J Escarce; Jennifer E Pace; Matthew D Solomon; Marianne Laouri; Pamela B Landsman; Steven M Teutsch
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

5.  Risk adjustment of Medicare capitation payments using the CMS-HCC model.

Authors:  Gregory C Pope; John Kautter; Randall P Ellis; Arlene S Ash; John Z Ayanian; Lisa I Lezzoni; Melvin J Ingber; Jesse M Levy; John Robst
Journal:  Health Care Financ Rev       Date:  2004
  5 in total
  36 in total

1.  Sources of drug coverage among Medicare beneficiaries with ESRD.

Authors:  Benjamin L Howell; Christopher A Powers; Eric D Weinhandl; Wendy L St Peter; Diane L Frankenfield
Journal:  J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 10.121

2.  Use of prescription drug samples and patient assistance programs, and the role of doctor-patient communication.

Authors:  Walid F Gellad; Haiden A Huskamp; Angela Li; Yuting Zhang; Dana Gelb Safran; Julie M Donohue
Journal:  J Gen Intern Med       Date:  2011-07-13       Impact factor: 5.128

3.  Nonlinear pricing in drug benefits and medication use: the case of statin compliance in Medicare Part D.

Authors:  Kyoungrae Jung; Roger Feldman; A Marshall McBean
Journal:  Health Serv Res       Date:  2013-12-19       Impact factor: 3.402

4.  Demand for prescription drugs under non-linear pricing in Medicare Part D.

Authors:  Kyoungrae Jung; Roger Feldman; A Marshall McBean
Journal:  Int J Health Care Finance Econ       Date:  2013-11-09

5.  In-gap discounts in Medicare Part D and specialty drug use.

Authors:  Jeah Jung; Wendy Yi Xu; Chelim Cheong
Journal:  Am J Manag Care       Date:  2017-09       Impact factor: 2.229

6.  How the Medicare Part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries.

Authors:  Yuting Zhang; Judith R Lave; Joseph P Newhouse; Julie M Donohue
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2009-12-14       Impact factor: 4.077

7.  Medicare Part D--lessons learned and guidance for health-care reform.

Authors:  William H Shrank; Jennifer M Polinski
Journal:  J Gen Intern Med       Date:  2010-01       Impact factor: 5.128

8.  Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications.

Authors:  Pinar Karaca-Mandic; Tami Swenson; Jean M Abraham; Robert L Kane
Journal:  Health Serv Res       Date:  2012-12-26       Impact factor: 3.402

9.  Responses to Medicare drug costs among near-poor versus subsidized beneficiaries.

Authors:  Vicki Fung; Mary Reed; Mary Price; Richard Brand; William H Dow; Joseph P Newhouse; John Hsu
Journal:  Health Serv Res       Date:  2013-05-13       Impact factor: 3.402

10.  The Medicare drug benefit (Part D) and treatment of heart failure in older adults.

Authors:  Julie M Donohue; Yuting Zhang; Judith R Lave; Walid F Gellad; Aiju Men; Subashan Perera; Joseph T Hanlon
Journal:  Am Heart J       Date:  2010-07       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.